Auro Laboratories Ltd vs Bharat Parenterals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Auro Laboratories Ltd is ₹ 239.1 as of 30 Apr 15:30 . The P/E Ratio of Auro Laboratories Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Bharat Parenterals Ltd changed from 9.4 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 years The Market Cap of Auro Laboratories Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Bharat Parenterals Ltd changed from ₹ 192 crore on March 2021 to ₹ 680.55 crore on March 2025 . This represents a CAGR of 28.80% over 5 years The revenue of Auro Laboratories Ltd for the Dec '25 is ₹ 0 crore as compare to the Mar '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Bharat Parenterals Ltd for the Dec '25 is ₹ 66.52 crore as compare to the Mar '25 revenue of ₹ 105.91 crore. This represent the decline of -37.19% The ebitda of Auro Laboratories Ltd for the Dec '25 is ₹ 0 crore as compare to the Mar '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Bharat Parenterals Ltd for the Dec '25 is ₹ 3.07 crore as compare to the Mar '25 ebitda of ₹ 4.16 crore. This represent the decline of -26.2% The net profit of Auro Laboratories Ltd changed from ₹ 0.75 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of -100.00% The net profit of Bharat Parenterals Ltd changed from ₹ -8.84 crore to ₹ -9.67 crore over 7 quarters. This represents a CAGR of 5.26% The Dividend Payout of Auro Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Bharat Parenterals Ltd changed from 1.78 % on March 2023 to 2.6 % on March 2025 . This represents a CAGR of 13.46% over 3 years .

About Auro Laboratories Ltd

Auro Laboratories Limited, founded in 1992, has been manufacturing and providing generic Active Pharmaceutical Ingredients (API).
Currently, the Company is specializing in producing Anti Diabetics like Metformin HCL. It is the first-line treatment for type 2 diabetes.
The Company is headquartered in Mumbai and it has manufacturing facility at Palghar in Maharashtra.
The facility has all the required certifications from Indian authorities and European registration organization Since inception, the Company focused on providing quality pharmaceuticals while maintaining high manufacturing standards.
Company presently has 1800 MTPA of Metformin HCL manufacturing capacity, with projects underway to expand the capacity to 3600 MTPA. The Company's primary focus was on Anti-Diabetic Drugs, which estimated to be one of the fastest growing therapeutic segments.

About Bharat Parenterals Ltd

Bharat Parenterals Limited was incorporated in September, 1992 in Gujarat and promoted by Ramesh Desai and Bharat Desai.
The Company is engaged in the business of manufacturing drugs, pharmaceutical formulations and ayurvedic products at its plant in Baroda.
It has set-up a fully integrated and modern plant as per WHO standards at Haripura near Baroda for manufacturing pharmaceutical formulations, life saving drugs, parenterals and antibiotics. In 2016, Varenyam Healthcare Private Limited was incorporated as wholly owned subsidiary company on 09 July, 2016.
Innoxel Lifesciences was incorporated as wholly owned subsidiary company effective 16th October, 2020.
Varenyam Biolifesciences got incorporated as wholly owned subsidiary company effective from 28th June, 2022.

FAQs for the comparison of Auro Laboratories Ltd and Bharat Parenterals Ltd

Which company has a larger market capitalization, Auro Laboratories Ltd or Bharat Parenterals Ltd?

Market cap of Auro Laboratories Ltd is 149 Cr while Market cap of Bharat Parenterals Ltd is 833 Cr

What are the key factors driving the stock performance of Auro Laboratories Ltd and Bharat Parenterals Ltd?

The stock performance of Auro Laboratories Ltd and Bharat Parenterals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Auro Laboratories Ltd and Bharat Parenterals Ltd?

As of May 3, 2026, the Auro Laboratories Ltd stock price is INR ₹239.1. On the other hand, Bharat Parenterals Ltd stock price is INR ₹1208.65.

How do dividend payouts of Auro Laboratories Ltd and Bharat Parenterals Ltd compare?

To compare the dividend payouts of Auro Laboratories Ltd and Bharat Parenterals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.